.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

ASCO GI

Oncology Biosimilar Roundup for January 2021

February 2nd 2021

Article

Findings from biosimilar studies of Kanjinti (trastuzumab) and Mvasi and Zirabev (bevacizumab) rounded out our oncology biosimilar coverage in January.

Study: Bevacizumab Biosimilar Finds Acceptance in First-Line Treatment of mCRC

January 30th 2021

Article

Investigators noted comparable use of bevacizumab biosimilar and reference products among patients treated for metastatic colorectal cancer (mCRC).

Investigators Study Risks of Hypertension, Proteinuria With Bevacizumab

January 19th 2021

Article

The study was designed to elucidate incidence of hypertension and proteinuria in patients treated with bevacizumab reference vs biosimilar products.

Swift Uptake for Mvasi Suggests Provider Comfort With Use

January 18th 2021

Article

Investigators looked at the first 9 months of use following the launch of the bevacizumab biosimilar Mvasi to gauge physician comfort with this agent across tumor types.